French vaccine developer Valneva SA will raise $85m in a financing arrangement with Deerfield and OrbiMed and go Nasdaq to co-fund its Lyme disease programme.
European venture capital firm Sofinnova Partners announced the promotion of Michael Krel to Partner of the Industrial Biotechnology team. Krel previously served as Principal on the team, where he focused on early-stage deals in Europe and North America.
Researchers at the University of Luebeck have revealed the structure of the IMP dehydrogenase, a central target of T. brucei, which causes sleeping sickness.
Scientists at Imperial College London have created a worldwide atlas of dengue virus transmission with much higher spatial resolution than any previous regional- or global-scale estimates.
The ENABLE project has achieved its initial goals to identify three antibacterial leads, select two antibacterial development candidates and advance one compound into Phase I development.
Ipsen has named steven Hildemann as Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance, effective March 2020.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2020-01-28 08:50:002020-01-28 08:50:00Ipsen: New VP and CMO incoming
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2020-01-27_um_09.23.22.png385431Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-01-27 09:01:082020-01-27 09:01:08iOnctura SA bags €15m in Series A round
Valneva raises US$85m
Latest NewsFrench vaccine developer Valneva SA will raise $85m in a financing arrangement with Deerfield and OrbiMed and go Nasdaq to co-fund its Lyme disease programme.
EMA greenlights 15 new meds
Latest NewsThe EMA’s human medicines committee (CHMP) recommended fifteen medicines for approval at its January 2020 meeting.
Sofinnova: Industrial biotech promotion
AppointmentsEuropean venture capital firm Sofinnova Partners announced the promotion of Michael Krel to Partner of the Industrial Biotechnology team. Krel previously served as Principal on the team, where he focused on early-stage deals in Europe and North America.
European Biotechnology Guide 2020
Sponsored PublicationsThe 10th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.
Sleeping sickness target deciphered
Latest NewsResearchers at the University of Luebeck have revealed the structure of the IMP dehydrogenase, a central target of T. brucei, which causes sleeping sickness.
UK researchers present dengue virus transmission map
Latest NewsScientists at Imperial College London have created a worldwide atlas of dengue virus transmission with much higher spatial resolution than any previous regional- or global-scale estimates.
AMR: IMI’s Enable project reaches endpoints
Latest NewsThe ENABLE project has achieved its initial goals to identify three antibacterial leads, select two antibacterial development candidates and advance one compound into Phase I development.
MercachemSyncom, Bionetix, and ProQinase ink AML contract
Latest NewsBionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing
Ipsen: New VP and CMO incoming
AppointmentsIpsen has named steven Hildemann as Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance, effective March 2020.
iOnctura SA bags €15m in Series A round
Latest NewsMerck KGaA’s 2017 Swiss cancer spin-out iOnctura SA has raised €15m to bring its PI3K? inhibitor and autotaxin inhibitor to the clinic.